Patents by Inventor Martin Teall

Martin Teall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR
    Publication number: 20240059677
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof wherein in, R1, R2, R3, L and X are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy particularly for use in treating disorders associated with nicotinic acetylcholine receptor ?6 (nAChR?6) activity.
    Type: Application
    Filed: September 10, 2021
    Publication date: February 22, 2024
    Inventors: Roland Werner Burli, Martin Teall, Nicola Brice
  • SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
    Publication number: 20230073334
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof. in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Application
    Filed: October 10, 2022
    Publication date: March 9, 2023
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
    Patent number: 11512066
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: November 29, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions
    Patent number: 11465994
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: October 11, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Martin Teall, Kathryn White, Stephen Mack, Gemma Liwicki, Anne Stephenson, Louise Dickson
  • SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
    Publication number: 20200190059
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 18, 2020
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions
    Patent number: 10562882
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: February 18, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Anne Goldby, Kerry Jenkins, Martin Teall
  • Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
    Patent number: 10544126
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 28, 2020
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS
    Publication number: 20190345148
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R1, R2, R3, R4, R5 and R6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 14, 2019
    Inventors: Martin Teall, Kathryn White, Stephen Mack, Gemma Liwicki, Anne Stephenson, Louise Dickson
  • Sulfonyl piperidine derivatives and their use for treating prokineticin mediated gastrointestinal disorders
    Patent number: 10335402
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: July 2, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Philip Mitchell, Martin Teall
  • 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
    Patent number: 10308635
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Martin Teall
  • SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES
    Publication number: 20190084962
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
    Patent number: 10208016
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: February 19, 2019
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Martin Teall
  • INDANE DERIVATIVES AS MGLUR7 MODULATORS
    Publication number: 20190031599
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: January 24, 2017
    Publication date: January 31, 2019
    Inventors: Anne Goldby, Gemma Liwicki, Stephen Mack, Martin Teall, Katy White
  • Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
    Patent number: 10167273
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which q, R11, R12, R13 and R14 are as defined in the specification, for use in therapy.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: January 1, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Colm Carroll, Anne Goldby, Martin Teall
  • Piperidine and azepine derivatives as prokineticin receptor modulators
    Patent number: 10160745
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: December 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Sarah Bousba, Anne Goldby, Kerry Jenkins, Natasha Kinsella, Martin Teall
  • 1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS
    Publication number: 20180251445
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification, compositions containing them and their use in therapy.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 6, 2018
    Inventor: Martin Teall
  • PIPERIDINE AND AZEPINE DERIVATIVES AS PROKINETICIN RECEPTOR MODULATORS
    Publication number: 20180009780
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions N containing them and their use in therapy.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 11, 2018
    Inventors: Sarah Bousba, Anne Goldby, Kerry Jenkins, Natasha Kinsella, Martin Teall
  • SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS
    Publication number: 20170340621
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R2, R3, R4 and R5 are as defined in the specification for use in treating irritable bowel syndrome or inflammatory bowel disease.
    Type: Application
    Filed: November 11, 2015
    Publication date: November 30, 2017
    Inventors: Philip Mitchell, Martin Teall
  • Piperidine and azepine derivatives as prokineticin receptor modulators
    Patent number: 9790201
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, X, R1, R2, R3 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: October 17, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Sarah Bousba, Anne Goldby, Kerry Jenkins, Natasha Kinsella, Martin Teall
  • Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions
    Publication number: 20170166553
    Abstract: The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R3, R4 and R5 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: November 26, 2014
    Publication date: June 15, 2017
    Inventors: Anne Goldby, Kerry Jenkins, Martin Teall